Actavis price target raised to $198 from $180 at Argus Argus increased its price target on Actavis after raising its 2013 adjusted EPS estimate above the company's guidance. The firm is upbeat about the outlook for generic drug companies in general, and predicts that Actavis will deliver mid-teens organic earnings growth in the near-term. It keeps a Buy rating on the stock.
News For ACT From The Last 14 Days
Check below for free stories on ACT the last two weeks.
Actavis files to sell 843,085 ordinary shares The offering is related to shares that may be issued upon the exercise of stock options granted under certain equity plans of Forest Laboratories to former employees or former directors of Forest.